Stryker Corporation — Key Risks
Healthcare Pricing Pressure Is Squeezing Margins From Multiple Directions
Hospitals, governments, and insurers are all pushing hard to pay less for medical devices. China has implemented a volume-based procurement process specifically designed to force prices down, and consolidation among hospital systems gives buyers more bargaining power. Stryker has already had to reduce prices on certain products due to competition, and it cannot guarantee it can pass rising costs on to customers — meaning margin pressure can come from both ends simultaneously.
Sole-Source Suppliers Create Fragile Links in the Supply Chain
Several critical materials, components, and services — including sterilization services — come from a single supplier with no easy backup. If that supplier faces financial trouble, a natural disaster, or a trade embargo, Stryker may not be able to manufacture or ship affected products. Switching to a new supplier is not as simple as making a phone call; FDA regulations require validation of new materials and processes, which takes significant time and money.
Tariffs and Global Trade Tensions Add Unpredictable Cost Pressure
Stryker manufactures and sells products across dozens of countries, with facilities in the U.S., China, Germany, Ireland, Mexico, and elsewhere. Recently enacted U.S. tariffs and retaliatory measures from other governments directly threaten the cost structure of this global footprint. Roughly 24% of net sales are denominated in foreign currencies, adding currency exchange volatility on top of tariff risk.
A Major ERP System Overhaul Carries Real Execution Risk
Stryker is in the middle of replacing its core ERP system (the software that runs order processing, shipping, invoicing, and financial reporting across the entire company). This kind of implementation is notoriously complex and disruptive — if it goes wrong, the company could temporarily lose the ability to process orders, ship products, send invoices, or fulfill contracts properly.
Product Liability Lawsuits Are an Ongoing and Evolving Threat
Stryker is currently defending multiple product liability cases, including claims related to its Rejuvenate and ABGII Modular-Neck hip stems and legacy products from its Wright Medical acquisition. Making this harder to manage, the European Union revised its Product Liability Directive in 2024 (to be fully adopted by December 2026) and introduced a new class-action framework, exposing the company to broader and potentially more expensive litigation across Europe.
Acquisition Integration — Especially the 2025 Inari Deal — May Not Deliver Expected Returns
Stryker grows significantly through acquisitions and closed its Inari Medical acquisition in 2025. Integrating a new business requires management time, financial resources, and operational coordination that can distract from the core business. The filing explicitly warns that anticipated benefits, cost savings, and synergies may not materialize, and that key employees from acquired companies may leave.
German Tax Audit Could Result in a Significant Unexpected Bill
The German Federal Central Tax Office completed audits covering tax years 2010 through 2017 and issued assessments against Stryker. The company is contesting these through appeals and potentially litigation, but there is no guarantee it will succeed. If it loses, foreign tax credits that could offset the liability may not be available in time or at all, creating a potential one-time financial hit.